Opinion|Videos|January 10, 2025
ASC4FIRST Trial & Asciminib New FDA Approval: Evaluating Asciminib in First-Line CML Treatment
Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you tell us about the trial design, key end points, and your impressions of the data?
- With the recent FDA approval of asciminib in the first-line (1L) setting, how will you incorporate this into your practice?
- Are there particular patients whom you would consider for asciminib vs first- or second-generation tyrosine kinase inhibitors?
- Please share any anticipated similarities or differences in your clinical practice now that asciminib has received FDA approval in the 1L setting.
Advertisement
Related to this article
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
2
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
3
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
4
Dr Bianchi on the Mechanism of Anselamimab in AL Amyloidosis
5